文献速递复苏、休克与脓毒症心脑血管急症重症综合管理与镇静镇痛

心脏重症监护室严重休克患者使用去甲肾上腺素与结局的关联

Outcomes Associated With Norepinephrine Use Among Cardiac Intensive Care Unit Patients with Severe Shock.
PubMed 文献 · Shock · 2021-01-01
一句话结论在需大剂量升压药的心脏ICU严重休克患者中,使用去甲肾上腺素与住院死亡率降低相关(aOR 0.46),但非大剂量组无此关联。

该回顾性队列纳入2007-2015年Mayo Clinic CICU接受升压药治疗的2090例患者,44%需大剂量升压药(HDV,定义为任一升压药峰值累积升压药指数为4)。HDV患者住院死亡率42% vs 16%。多变量分析中,HDV患者峰值去甲肾上腺素当量剂量每增加0.01 mcg/kg/min住院死亡率升高(aOR 1.02),使用去甲肾上腺素与住院死亡率降低相关(aOR 0.46,95%CI 0.31-0.72)。非HDV患者中,校正疾病严重程度后去甲肾上腺素使用及峰值NEE与死亡率无关。提示更严重休克患者可能从优先使用去甲肾上腺素中获益。

要点

  • HDV定义为任一升压药峰值累积升压药指数为4,本队列44%患者符合。
  • HDV患者住院死亡率42%,显著高于非HDV患者的16%(未校正OR 3.87)。
  • HDV患者中,去甲肾上腺素使用与住院死亡率降低独立相关(aOR 0.46,95%CI 0.31-0.72)。
  • HDV患者峰值去甲肾上腺素当量剂量每增加0.01 mcg/kg/min,住院死亡率aOR 1.02。
  • 非HDV患者中,校正后去甲肾上腺素使用及峰值NEE与死亡率无关联。

适用人群与场景

  • 2007-2015年Mayo Clinic心脏ICU接受升压药治疗的患者,中位年龄69岁(IQR 59-78),35%女性。
  • 严重休克定义为需大剂量升压药(HDV,任一升压药峰值累积升压药指数为4),占44%。

诊断标准与关键阈值

  • HDV定义:任一升压药峰值累积升压药指数(Cumulative Vasopressor Index)为4。
  • 峰值去甲肾上腺素当量(NEE)剂量用于比较升压药剂量。

处置流程与药物剂量

  • 原文未提及

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 回顾性队列研究,单中心(Mayo Clinic CICU),纳入2090例接受升压药治疗的患者。
  • HDV患者住院死亡率42% vs 非HDV 16%(未校正OR 3.87,95%CI 3.16-4.75,P<0.01)。
  • HDV患者多变量分析:峰值NEE每增加0.01 mcg/kg/min,住院死亡率aOR 1.02(95%CI 1.01-1.02,P<0.01);使用去甲肾上腺素与住院死亡率降低相关(aOR 0.46,95%CI 0.31-0.72,P<0.01)。
  • 非HDV患者校正疾病严重程度后,峰值NEE及去甲肾上腺素使用与死亡率无关。

证据类型、等级与局限

  • 回顾性队列研究,单中心,样本量2090例;局限性包括回顾性设计、单中心、未提及盲法或前瞻性验证。

对床旁实践的改变

  • 在心脏ICU需大剂量升压药的严重休克患者中,优先使用去甲肾上腺素可能与更低住院死亡率相关;非大剂量升压药患者中未观察到此关联。
  • 峰值去甲肾上腺素当量剂量越高,住院死亡率越高,提示升压药需求增加是死亡风险标志。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: Recent data suggests improved outcomes among cardiac intensive care unit (CICU) patients treated with norepinephrine, especially patients with severe shock. We aimed to describe the association between norepinephrine and mortality in CICU patients with severe shock, defined as those requiring high-dose vasopressors (HDV).

MATERIALS AND RESULTS: We retrospectively evaluated Mayo Clinic CICU patients treated with vasopressors from 2007 to 2015. HDV was defined as a peak Cumulative Vasopressor Index of four for any vasopressor. Peak norepinephrine equivalent (NEE) dose was used to compare vasopressor doses. Multivariable logistic regression was used to determine predictors of hospital mortality.

RESULTS: We included 2,090 patients with a median age of 69 years (IQR 59-78), including 35% females; 44% of patients received HDV. Hospital mortality was higher among patients receiving HDV (42% vs. 16%, unadjusted OR 3.87, 95% CI 3.16-4.75, P < 0.01). On multivariable analysis in HDV patients, hospital mortality increased with rising peak NEE (adjusted OR 1.02 per 0.01 mcg/kg/min, 95% CI 1.01-1.02, P < 0.01) and the use of NE was associated with lower hospital mortality (adjusted OR 0.46, 95% CI 0.31-0.72, P < 0.01). After adjustment for illness severity, peak NEE and norepinephrine use were not associated with mortality among patients who did not require HDV.

CONCLUSIONS: Mortality is high among CICU patients requiring HDV, and rises with increasing vasopressor requirements. Use of NE was associated with lower mortality among patients requiring HDV, but not among those without HDV, implying that patients with more severe shock may benefit from preferential use of NE.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Burstein B, Vallabhajosyula S, Ternus B, et al. Outcomes Associated With Norepinephrine Use Among Cardiac Intensive Care Unit Patients with Severe Shock. Shock. 2021. PMID: 34524266. doi:10.1097/SHK.0000000000001767

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。